✦ LIBER ✦

Pharmacokinetics of single and multiple oral doses of zd 1839 (‘Iressa’), a specific epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), in healthy male volunteers

✍ Scribed by H.C. Swaisland; R. Smith; H. Jones; J. Farebrother; A. Laight

Book ID: 117658098
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 184 KB
Volume: 37
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(01)80728-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics and Tolerability of the

Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers

✍ Ms Helen Swaisland, Alison Laight, Lesley Stafford, Helen Jones, Charles Morris, 📂 Article 📅 2001 🏛 Springer International Publishing AG 🌐 English ⚖ 202 KB

Antitumor activity of the selective epid

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo

✍ Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell

Preclinical rationale for a combined tre

Preclinical rationale for a combined treatment with irinotecan and the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (Iressa) in irinotecan-refractory human colon cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 157 KB

ZD1839 (‘Iressa’), an orally-active, sel

ZD1839 (‘Iressa’), an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours: preliminary tolerability, efficacy and pharmacokinetic results

✍ G. Giaccone; J.L. Gonzales-Larriba; E.F. Smit; A.T. van Oosterom; M. Martins; G. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 338 KB

Pharmacodynamic studies of the specific

Pharmacodynamic studies of the specific oral EGFR tyrosine kinase inhibitor (EGFR-TKI) zd1839 (‘Iressa’) in skin from cancer patients participating in phase I trials: histopathological and molecular consequences of receptor inhibition

✍ J. Albanell; F. Rojo; S. Averbuch; A. Feyereislova; R. Herbst; P. LoRusso; D. Ri 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 177 KB

Inhibition of proliferation and inductio

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level

✍ Manuela Campiglio; Alberta Locatelli; Clelia Olgiati; Nicola Normanno; Giulia So 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') has clinical activity in a wide range of tumor types, although the mechanism(s) by which it exerts its ant